Rocket Pharmaceuticals, Inc. (RCKT)
Automate Your Wheel Strategy on RCKT
With Tiblio's Option Bot, you can configure your own wheel strategy including RCKT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RCKT
- Rev/Share 0.0827
- Book/Share 3.1905
- PB 0.9121
- Debt/Equity 0.0711
- CurrentRatio 6.3862
- ROIC -0.7035
- MktCap 314000640.0
- FreeCF/Share -1.8565
- PFCF -1.5235
- PE -1.2556
- Debt/Assets 0.0599
- DivYield 0
- ROE -0.66
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RCKT | BofA Securities | Neutral | Buy | -- | $10 | Aug. 20, 2025 |
| Downgrade | RCKT | BofA Securities | Buy | Neutral | -- | $4 | July 25, 2025 |
| Downgrade | RCKT | Evercore ISI | Outperform | In-line | -- | $5 | May 30, 2025 |
| Downgrade | RCKT | Jefferies | Buy | Hold | -- | $2.5 | May 28, 2025 |
| Downgrade | RCKT | Leerink Partners | Outperform | Market Perform | -- | $8 | May 28, 2025 |
| Downgrade | RCKT | Morgan Stanley | Overweight | Equal Weight | -- | $7 | May 28, 2025 |
| Downgrade | RCKT | Goldman | Neutral | Sell | -- | $2 | May 28, 2025 |
| Downgrade | RCKT | JP Morgan | Overweight | Neutral | -- | -- | May 28, 2025 |
| Downgrade | RCKT | Needham | Buy | Hold | -- | -- | May 27, 2025 |
| Downgrade | RCKT | TD Cowen | Buy | Hold | -- | -- | May 27, 2025 |
News
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman
Published: July 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.
Read More
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: July 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between September 17, 2024 and May 26, 2025, inclusive (the “Class Period”).
Read More
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , July 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No.
Read More
RCKT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In RCKT To Contact Him Directly To Discuss Their Options
Published: July 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, …
Read More
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Read More
Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT
Published: July 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 22, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). IF YOU SUFFERED A LOSS ON YOUR ROCKET INVESTMENTS, CLICK HERE BEFORE AUGUST 11, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk.
Read More
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming Deadline
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming Deadline
Read More
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RCKT
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Read More
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
Published: July 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Read More
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Read More
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action– Hagens Berman
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company's shares saw their investment crash over 60% that day.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 17, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) have opportunity to lead the securities fraud class action lawsuit.
Read More
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKT
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
NASDAQ: RCKT INVESTOR ALERT: Berger Montague Advises Rocket Pharmaceuticals (RCKT) Investors of August 11, 2025 Deadline
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, July 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC , a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket Pharmaceuticals” or the “Company”) for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses.
Read More
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601, the Company's investigational adeno-associated virus (AAV)-based gene therapy for the treatment of PKP2-arrhythmogenic cardiom.
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 11, 2025 to Discuss Your Rights
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) between February 27, 2025 to May 26, 2025, inclusive (the “Class Period”).
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Read More
Lost Money on Rocket Pharmaceuticals, Inc.(RCKT)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).
Read More
Faruqi & Faruqi Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT
Published: July 15, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ("Rocket" …
Read More
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.
Read More
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming Deadline
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming Deadline
Read More
Rocket Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - RCKT
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
ROSEN, A TOP-RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
Published: July 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Read More
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”).
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Published: July 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Read More
About Rocket Pharmaceuticals, Inc. (RCKT)
- IPO Date 2015-02-18
- Website https://rocketpharma.com
- Industry Biotechnology
- CEO Gaurav D. Shah
- Employees 299